JPRN-UMIN000026499已完成未知
Tapering Multiple Benzodiazepine Drugs study through investigating Cognition and Risk of Side Effects for Depression - Tapering Multiple Benzodiazepine Drugs study through investigating Cognition and Risk of Side Effects for Depression
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who contract disease affecting cognitive disfunction, for example epilepsy, alcohol dependence syndrome and so on. Pregnant patients.
研究者
相似试验
尚未招募
不适用
The Benzodiazepine Agent Tapering Trial in Japamental diseaseJPRN-UMIN000017765ational Center of Neurology and Psychiatry20
进行中（未招募）
1 期
Benzodiazepine maintenance treatment for patients with benzodiazepine dependence undergoing opioid agonist therapy (BMX-BAR)Benzodiazepine dependenceEUCTR2021-004981-37-NOHelse Bergen HF90
尚未招募
4 期
Big Five Personality Factors in Benzodiazepine abuse: Brief Intervention controlled studyCTRI/2023/10/058797Central Institute of Psychiatry
进行中（未招募）
不适用
Randomized Treatment Interruption of Natalizumab - RESTOREatalizumab is a highly efficacious therapy used in the treatment of patients with relapsing multiple sclerosis (MS).This is a prospective randomized study in subjects with relapsing forms of MS who have been receiving natalizumab treatment for at least 12 months with no MS relapses during these 12 months.MedDRA version: 12.1Level: LLTClassification code 10063399Term: Relapsing-remitting multiple sclerosisEUCTR2009-017490-38-DEBiogen Idec200
已完成
不适用
Stopping Benzodiazepines and Related Molecules Among Elderly Living in Residential InstitutionsElderlyDrug Therapy SyndromeSubstance-Related DisordersSubstance Withdrawal SyndromeNCT02715440Assistance Publique - Hôpitaux de Paris116